Lactobacillus reuteri DSM 17938 and Reduced Hospitalization Duration

Doses used in studies

CFU/day: 100 million–2 billion (median 1.1 billion, IQR 575 million–1.5 billion) — 2 studies

Safety in these studies

antibiotic-associated side effectsNo significant differencesignificant decrease of antibiotic-associated side effects
showing a significant decrease of antibiotic-associated side effects and a tendency to increase the eradication rate
from: Use of Limosilactobacillus reuteri DSM 17938 in paediatric gastrointestinal disorders: an
Overall tolerabilityReported
all these studies have shown the excellent safety of LR DSM 17938 even at higher dosages.
from: Use of Limosilactobacillus reuteri DSM 17938 in paediatric gastrointestinal disorders: an

1 of 1 paper

Use of Limosilactobacillus reuteri DSM 17938 in paediatric gastrointestinal disorders: an updated review.